Saturday, 20 October 2018

Cladribine is getting rid of oligoclonal bands

Off-label Cladribine use has been championed by DrK and this in part led to the re-emergence of the oral variant, which remerged after a 6 year holiday.

During this time we have generated a large cohort  (See Stephanias ECTRIMS work below) of people taking this drug and we have defined a new working mechanism for cladribine .


Whilst memory B cell targeting is not uniqure to Cladribine, it has one potential advantage over other highly effective MS drugs.


This is that it enters (about 25% the blood level) and can be active within the CNS (Finglomido enters the brain but its main mechanism is in the lymph glands) . Therefore it can target elements of disease that are relevant to progressive MS.


However, the center of off-label cladribine was not the East-End of London, it was the East-End of Europe. Indeed our friends in Poland have been using of-label cladribine for years and they have asked what happens to the oligoclonal bands.


Interested read on.

Friday, 19 October 2018

Whats Lost is Lost, Why CRAB can sometimes mean CRAP

This German studies shows real life data that dimethyl fumarate is better than the CRAB drugs plus teriflunomide......So why are we still using them?

Thursday, 18 October 2018

Why is Prof G dissatisfied?

I have been espousing the message that time is Brain in the treatment of MS, but the NHS makes it difficult to practice what you preach. MS services in the NHS are not configured at present to react quickly in terms of new referrals and as a result, MSers pay the price. In the last few months, two MSers have lost brain and spinal cord because of how long it has taken them to get into the Barts-MS system. This upsets me and leaves me feeling very dissatisfied with my NHS practice. 



Guest Post: DrMaria from Spain explains about relapses

Hello everybody

First of all, I would like to introduce myself. I am Maria Mateo, I am a Neurology registrar from Spain and I have the pleasure of spending three months at Barts-MS to learn about MS.
As a part of my stay here, I have been attending MS clinics. As we know, MS patients can experience a broad variety of symptoms during their disease that can be difficult to explain. Thus, I have noticed that some MS patients have difficulties interpreting whether their symptoms are due to a new relapse or not, or if their symptoms are related to something else. Therefore, I have thought that it would be useful to clarify some main concepts around MS relapses.




Wednesday, 17 October 2018

ECTRIMS2018 Time is Your Brain,

There is no doubt that some people do OK on CRAB (copaxone, rebif, avonex and betaferon) drugs, but many do not and there are a number of more effective agents out there. 

However there are consequences of not getting disease under control as shown at ECTRIMS 2018

Guest post: A different MS Chariot

I have been encouraged by ProfG to write a post about my “MS Chariot” experience. It's a good example of an activity that those with limited leg function can enjoy, but for which it is important to preserve upper body function.



Monday, 15 October 2018

triMS-online: helping female academics

Another development at ECTRIMS 2018, which I heard about via the ECTRIMS grapevine, is that female academics are mobilising and have formed a group to demand gender equality at the top table of MS academia. Good!




Sunday, 14 October 2018

Early reflections on ECTRIMS 2018

I am writing this post on the flight back to London from Berlin. Being trapped in a tin tube at over 10,000m above sea level is always a good time to think.

under&over - ProfG's #1 non-scientific highlight at #ECTRIMS2018


Guess what my #1_scientific_highlight was at #ECTRIMS2018?